Associated tags: Infection, Hepatitis B, HIV, Biotechnology, Immune system, COVID-19, SAN, Pharmaceutical industry, Vir, Research, Vaccine
Locations: NEW ZEALAND, VIR, SAN FRANCISCO, MAB, LOS ANGELES, LONDON, NEW YORK, UNITED KINGDOM, FRANCE, OREGON, MISSOURI, SWITZERLAND, BARDA, UNITED STATES, NORTH AMERICA, CALIFORNIA, MASSACHUSETTS, PENNSYLVANIA, GILEAD
AIDS,
Health,
Infectious Diseases,
COVID-19,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Infection,
HIV Vaccine Trials Network,
Administration,
Cirrhosis,
ASPR,
Bangladesh Technical Education Board,
Congress,
HHS,
COVID,
EASL,
Investment,
Safety,
Peginterferon-alfa,
Abstract,
MedRxiv,
Development,
Hepatitis,
GSK,
Vir,
HCMV,
Bill,
Data analysis,
Influenza,
Conditional sentence,
HIV,
MBA,
Metapneumovirus,
Vaccine Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
Key Points:
- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
- The Phase 2 MARCH Part B trial is fully enrolled with 48-week end of treatment data expected in the fourth quarter of 2024.
- Cash, cash equivalents and investments declined by approximately $118 million during the first quarter of 2024.
- Revenues: Total revenues for the quarter ended March 31, 2024, were $56.4 million compared to $63.0 million for the same period in 2023.
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m.
Key Points:
- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m.
- ET.
- A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.
Research,
Infectious Diseases,
FDA,
Clinical Trials,
Biotechnology,
AIDS,
Health,
Science,
Oncology,
Biochemistry,
Development,
Bayer,
HCV,
Rutgers University,
Biophysics,
Communication,
Baylor College of Medicine,
Beneficial ownership,
Infection,
HIV,
Name,
Therapy,
Harvard University,
Publication,
Research and development,
Supervisory board,
Drug development,
Natural science,
Doctor of Philosophy,
University,
Agriculture,
Cancer,
Bangladesh Technical Education Board,
Gilead Sciences,
Syntex,
Patient,
Pleasure,
MBA,
Annual general meeting,
HBV,
Kronos Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”).
Key Points:
- Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”).
- The nomination of the two new independent directors demonstrates Vir’s commitment to ongoing Board refreshment.
- Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, said: “We are incredibly excited about the prospect of adding such highly talented directors in Norbert and Ramy to the Board.
- Previously, he served on the board of directors of Nimbus Therapeutics, a biotechnology company he helped found in 2009.
Software,
Research,
General Health,
Pharmaceutical,
Technology,
Infectious Diseases,
Health Technology,
Clinical Trials,
Science,
Biotechnology,
AIDS,
FDA,
Health,
Donald Duck filmography,
Vir,
Conference,
Webcast,
Event Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024.
Key Points:
- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024.
- The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024.
- The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio .
- A recorded version of the call will be available on the website approximately two hours after the completion of the event and will be archived there for 30 days.
Biotechnology,
Infectious Diseases,
Health,
Pharmaceutical,
Clinical Trials,
Alanine transaminase,
HDV,
ALT,
Clinical research,
Cirrhosis,
Safety,
RNA,
CHD,
Patient,
Clinical trial,
Hepatitis,
Pharmaceutical industry Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated.
Key Points:
- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated.
- Initial data are expected in the second quarter of 2024.
- SOLSTICE is a Phase 2 multi-center, open-label trial designed to evaluate the safety, tolerability, and efficacy of tobevibart and elebsiran in adult participants (age 18 to 69) with CHD infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy.
- Depending on the cohort, trial participants are receiving multiple doses of tobevibart and elebsiran as either monotherapy or in combination administered via subcutaneous injection for up to 88 weeks.
Retrieved on:
Thursday, February 22, 2024
Biotechnology,
Pharmaceutical,
AIDS,
Health,
COVID-19,
Infectious Diseases,
Health Technology,
Clinical Trials,
Infection,
Bangladesh Technical Education Board,
RSV,
CHB,
Influenza,
Peginterferon-alfa,
HIV Vaccine Trials Network,
GSK,
Research,
Investment,
AASLD,
HDV,
MBA,
Cirrhosis,
HHS,
Administration,
Conditional sentence,
Hepatology,
RNA,
Respiratory syncytial virus,
ASPR,
COVID,
Patient,
Family,
HCMV,
Bill,
Development,
HIV,
Pharmaceutical industry Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Points:
- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
- Complete 24-week treatment data for 30 participants per regimen is expected in the fourth quarter of 2024.
- The MARCH Part B trial is ongoing with 48-week end of treatment data expected in the fourth quarter of 2024.
- Revenues: Total revenues for the quarter ended December 31, 2023 were $16.8 million compared to $49.4 million for the same period in 2022.
Retrieved on:
Tuesday, February 20, 2024
Research,
Infectious Diseases,
FDA,
Clinical Trials,
Biotechnology,
AIDS,
Health,
Pharmaceutical,
Science,
Infection,
Hepatitis B,
COVID-19,
Vir,
HIV,
MBA,
Family Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time with his family.
Key Points:
- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time with his family.
- “Phil has served as a formidable leader at Vir, where he played a major part in the development of sotrovimab during the peak of the COVID-19 pandemic.
- Now, after a period of reflection, I have decided to spend more time with my family,” said Dr. Pang.
- “I leave a very capable development team that will inform the strategy and enable a smooth transition for a new Chief Medical Officer.
Retrieved on:
Friday, February 23, 2024
Research,
Infectious Diseases,
FDA,
Clinical Trials,
Biotechnology,
AIDS,
Health,
Pharmaceutical,
Science,
Fontainebleau Miami Beach,
MBA,
Conference,
Vir,
Cryptocurrency Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of March:
Key Points:
- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of March:
TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston.
- Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat on Monday, March 4, at 2:50 p.m.
- Vir management will be hosting one-on-one investor meetings on Monday, March 11 and Tuesday, March 12.
- Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat on Tuesday, March 12, at 7:30 a.m.
Retrieved on:
Thursday, February 1, 2024
Technology,
Infectious Diseases,
Public Relations,
Investor Relations,
Communications,
Health Technology,
Software,
Health,
General Health,
Data Management,
Biotechnology,
Webcast,
Vir,
Event,
Donald Duck filmography Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter ended December 31, 2023, on February 22, 2024.
Key Points:
- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter ended December 31, 2023, on February 22, 2024.
- The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on February 22, 2024.
- The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio .
- Participants may access the conference call via webcast on the Events & Presentations page of Vir’s website at https://investors.vir.bio/events-presentations .
Retrieved on:
Wednesday, December 13, 2023
Research,
Infectious Diseases,
FDA,
Biotechnology,
AIDS,
Health,
Pharmaceutical,
Science,
Oncology,
Workforce,
Investment,
Infection,
MBA,
Growth,
Vir,
Fine chemical,
Vaccine,
Pharmaceutical industry Vir Biotechnology, Inc. (Nasdaq: VIR) today announced strategic imperatives to focus its capital allocation on programs with the highest potential for patient impact and value creation.
Key Points:
- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced strategic imperatives to focus its capital allocation on programs with the highest potential for patient impact and value creation.
- These are designed to optimize the Company’s cost structure by reducing the size of its workforce and the number of sites it operates.
- Vir expects to incur charges between $30 million to $40 million, primarily related to facility closures and to a lesser extent, employee severance costs.
- Vir expects to reduce its cost structure by at least $40 million annually.
